Birchler Brian 4
4 · IONIS PHARMACEUTICALS INC · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) EVP Brian Birchler Sells 6,179 Shares
What Happened Brian Birchler, Executive Vice President, Corporate and Development Operations at Ionis Pharmaceuticals (IONS), had 11,991 performance-based restricted stock units (PRSUs) vest on 2026-01-29 (awarded at $0 cost). On 2026-01-30 he sold 6,179 of those shares in open-market transactions for a weighted average price of $83.03, generating approximately $513,048 in proceeds. The award reflects a certified payout level of 167.27% of target for the PRSU performance period.
Key Details
- Transactions: 11,991 shares awarded (vested) on 2026-01-29; 6,179 shares sold on 2026-01-30.
- Prices/values: Award reported at $0 (vested RSUs). Sale weighted average price $83.03; sale proceeds ≈ $513,048. Sales ranged $83.00–$83.08 (footnote).
- Shares owned after transaction: Not specified in this filing.
- Footnotes: F1 — PRSU vesting based on relative total shareholder return vs. peer group; payout = 167.27% of target (range 0–200%). F2 — sale price is a weighted average across multiple transactions; reporting person will provide per-price detail on request.
- Filing timeliness: Reported on 2026-02-02 for transactions on 2026-01-29 and 2026-01-30; this appears to be within the typical two-business-day Form 4 filing window.
Context The 11,991 shares were earned via vesting of performance-based RSUs granted earlier (grant reported 2023-01-18); such awards are reported as acquisitions at $0 because they were issued, not purchased. The subsequent open-market sale of 6,179 shares is a disposition reported separately. The filing does not state a reason for the sale; filings typically do not indicate insider motives.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-29+11,991→ 72,426 total - Sale
Common Stock
[F2]2026-01-30$83.03/sh−6,179$513,048→ 66,247 total
Footnotes (2)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.00 to $83.08 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.